Minutes for the Research for Patient Benefit (RfPB) programme London Regional Advisory Committee meeting to discuss Stage 2 applications to Competition 47 and Stage 1 applications to Competition 48.
Date and Location
Thursday 22 September 2022 Virtual Meeting
In attendance
Committee members
Dr Chris Gale (Chair)
Dr Elizabeth Bancroft
Dr Jacqueline Birks
Dr Thomas Booth
Miss Eva Broeckelmann
Professor Kate Brown
Mr Martin Carroll
Dr Julia Chisholm
Professor Francesco D'Aiuto
Ms Mikaela Davies
Dr Anna De Simoni
Dr Martina Di Simplicio
Dr Johnny Downs
Dr Philip Kinghorn
Dr Rachel Philips
Dr Mariana Pinto Da Costa
Dr Claire Rosten
Dr Katie Sheehan
Dr Susan Shelmerdine
Professor Christina Victor
Dr Charlotte Warren-Gash
Dr Dominik Zenner
Secretariat
Mr Richard Foulsham (NIHR)
Dr Kasia Kuleszewicz (NIHR)
Ms Lavpreet Ranjit (NIHR)
Ms Sophie Tattersall (NIHR)
Observers
Dr Christopher Newby - RDS EM
Mrs Geri Barrett - RDS EE
Miss Diane Fox - RDS SE
Competition 47 Stage 2 applications considered
NIHR204370: Evaluation of a novel multi-component anxiety management programme for the treatment of anxiety disorder in people with Intellectual disability
Conflicts: None
Final outcome: Conditional support
NIHR204347: A randomised trial assessing the duration of anti-coagulation treatment for LV thrombus of ischaemic aetiology (DURATION-LVT Study)
Conflicts: Professor Francesco D'Aiuto
Final outcome: Reject
NIHR204342: Understanding the costs, health consequences and barriers to using RNA sequencing-based selection of rituximab for people with rheumatoid arthritis (R4-RA-Econ)
Conflicts: Professor Francesco D'Aiuto
Final outcome: Conditional support
Competition 48 Stage 1 applications considered
NIHR204994: Gasless macular hole surgery: a feasibility study
Conflicts: None
Outcome: Invite to Stage 2
NIHR204961: The Sickle I project: Prevalence of sight loss associated with sickle cell retinopathy and maculopathy and the impact on vision-related quality of life
Conflicts: None
Outcome: Invite to Stage 2
NIHR205004: The "Group Education and Treatment Initiation with Enhanced Support and Technology" intervention for patients with Obstructive Sleep Apnoea (OSA) to improve adherence to Continuous Positive Airway Pressure therapy: is the "GrEaTEST-OSA" intervention acceptable to patients and feasible?
Conflicts: Dr Philip Kinghorn
Outcome: Invite to Stage 2
NIHR204952: Contingency Management to increase naloxone carriage: development and testing of a new behavioural intervention (‘Contingency Management for Carry-on-you Naloxone’; CM4COYN)
Conflicts: Dr Johnny Downs
Outcome: Invite to Stage 2
NIHR204993: The feasibility of knee taping in painful patellofemoral osteoarthritis
Conflicts: None
Outcome: Invite to Stage 2
NIHR204980: Medical cannabis for anxiety in autistic adults: A pilot randomised controlled trial
Conflicts: Dr Johnny Downs, Dr Mariana Pinto da Costa
Outcome: Reject
NIHR204981: Diversity in Major Trauma patients: risks, responses, and recovery
Conflicts: None
Outcome: Reject
NIHR204990: DEVELOPING AN ACCEPTABLE CULTURALLY SENSITIVE INTERVENTION FOR SOUTH ASIAN WOMEN WITH COMMON MENTAL DISORDERS (CMD)
Conflicts: Dr Mariana Pinto da Costa
Outcome: Reject
NIHR204925: Management of compromised extraction sockets using novel ridge reconstruction technique: a randomised controlled trial
Conflicts: None
Outcome: Reject
NIHR204977: Development of Core Outcome Sets for trials on the management of Atrial fiBrillAtion in Critically Unwell patientS (COS-ABACUS)
Conflicts: None
Outcome: Invite to Stage 2
Outcomes Table
The tables below display the mean score for each application that was assessed in the regional assessment committee meeting, and excludes applications which were rejected during the scrutiny and triage processes. The number of applications receiving each mean score are listed. The RfPB fundable range is 6-10, although a score of 6-10 does not guarantee funding or an invitation to Stage 2. In exceptional circumstances and with approval from the Programme Director, applications may be invited/funded which fall below the fundable range.
In exceptional circumstances, applications which fall below the fundable range may be invited to Stage 2 or recommended for funding by the Committee. The Programme Director reviews in detail any applications recommended for funding with a score below 7.
Stage 2
| Score | Range | Number of applications |
|---|---|---|
| 9.0 - 10.0 | Fundable | 0 |
| 8.0 - 8.9 | Fundable | 1 |
| 7.0 - 7.9 | Fundable | 0 |
| 6.0 - 6.9 | Fundable | 1 |
| 5.0 - 5.9 | Rejected | 0 |
| 4.0 - 4.9 | Rejected | 0 |
| 3.0 - 3.9 | Rejected | 1 |
| 2.0 - 2.9 | Rejected | 0 |
| 1.0 - 1.9 | Rejected | 0 |
Stage 1
| Score | Range | Number of applications |
|---|---|---|
| 9.0 - 10.0 | Invited | 0 |
| 8.0 - 8.9 | Invited | 0 |
| 7.0 - 7.9 | Invited | 3 |
| 6.0 - 6.9 | Invited | 3 |
| 5.0 - 5.9 | Rejected | 0 |
| 4.0 - 4.9 | Rejected | 2 |
| 3.0 - 3.9 | Rejected | 1 |
| 2.0 - 2.9 | Rejected | 1 |
| 1.0 - 1.9 | Rejected | 0 |